Table 1.
Characteristics of patients
| Factors | Sorafenib | Combination Tx | p-value |
|---|---|---|---|
| Gender (male/female) | 50/8 | 19/3 | 0.985 |
| Age (years) | 68 (37–83) | 67.5 (53–82) | 0.564 |
| Etiology (HCV/HBV/Others) | 20/15/23 | 6/7/9 | 0.767 |
| ECOG PS (0, 1/2) | 54/4 | 21/1 | 0.579 |
| Child (A/B/C) | 43/15/0 | 20/2/0 | 0.102 |
| Serum Alb (g/dL) | 3.6 (2.2–4.5) | 3.9 (2.2–4.3) | 0.202 |
| Serum T-Bil (mg/dL) | 0.75 (0.3–2.8) | 0.65 (0.3–1.9) | 0.139 |
| ALBI grade (1/2/3) | 49/9/0 | 20/2/0 | 0.366 |
| Plt (×104/mL) | 12.7 (6.9–58.5) | 14.6 (7.0–24.1) | 0.880 |
| BCLC stagea (B1/B2/B3/C) | 15/4/0/39 | 0/8/0/14 | 0.526b |
| Max tumor size (cm) | 5.0 (2.0–15.0) | 6.0 (3.0–20.0) | 0.595 |
| Tumor number | 4 (1–20) | 6 (1–20) | 0.490 |
| EHM (yes/no) | 18/40 | 5/17 | 0.464 |
| MVI (yes/no) | 30/28 | 14/8 | 0.241 |
| Serum AFP (ng/mL) | 43.2 (1.3–1,200,000) | 39.6 (4.5–97,480) | 0.923 |
| Serum DCP (mAU/mL) | 898 (4.0–220,192) | 172 (19.0–71,386) | 0.165 |
| Prior treatment (yes/no) | 49/9 | 18/4 | 0.509 |
| Prior TACE number | 2 (0–8) | 2 (0–4) | 0.370 |
Notes: Results are reported as number or as median (range).
a
BCLC-B subclassification according to Kinki criteria.
b
Comparison between BCLC-B and BCLC-C.
Abbreviations: Tx, therapy; HCV, hepatitis C virus; HBV, hepatitis B virus; ECOG, Eastern Cooperative Oncology Group; PS, performance status; Alb, albumin; T-Bil, total bilirubin; ALBI, albumin–bilirubin; Plt, platelet; BCLC, Barcelona clinical liver cancer; EHM, extrahepatic metastasis; MVI, major vascular invasion; AFP, alpha-fetoprotein; DCP, des-gamma-carboxy prothrombin; TACE, transarterial chemoembolization.